Summary

Generic Drugs Market Research Report by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, Others), by Route of Administration (Oral, Topical, Parenteral, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and by Region (North America, Europe, Aia-Pacific, Rest of the World) Forecast till 2035

Market Analysis
The global generic drugs market is forecast to expand from USD 437.90 billion in 2024 to reach USD 1,148.55 billion by 2035 with a CAGR of 9.36%. Generic drugs are medications that contain the same active ingredients as brand-name drugs and provide the same therapeutic effects, dosage, and safety profile. They are introduced to the market after the original drug’s patent expires, offering a more affordable alternative without compromising quality or efficacy.
In the world generic medicines are becoming a popular choice due to the increased in chronic illnesses like cancer, cardiovascular diseases, neurological disorders, and autoimmune diseases. As the cost of treatment escalates, affordable alternatives become an absolute necessity and generics not only fulfill this requirement but also are therapeutically equivalent to the branded medicines. The growth of the industry is additionally supported by the actions that are taken by the manufacturers of the industry, such as launching new products, using lower-cost formulations, and increasing the production capacity.
However, despite the upsides, the growth of the sector could be restrained by voluntary withdrawal of products from the market owing to problems of quality, packaging, or manufacturing, which result in a loss of trust among patients and unstable supply. Along with this, a doctor's and patient's preference for branded drugs poses a problem to the pace of green penetration.
This changed because of deep R&D investments that go along with the progression of generics in the complex drug categories such as biologics and oncology therapies. The growth of the elderly population in developed as well as developing countries is a constant factor that leads to a sustained demand for their long-term treatment for multiple diseases. The governments are giving priority to the generics through their cost-containment strategies, substitution policies, and reimbursement incentives. The generic drugs market with these set targeted growth has combined drivers and opportunities overshadowing restraints, will still be at the center of ensuring global access to affordable healthcare.

Market Segmentation Insights
The global market is classified based on the route of administration, comprising oral, topical, parenteral, and others.
Depending on the indication, the global drugs market is segmented into central nervous system (CNS), cardiovascular, urology, oncology, respiratory, and others.
Based on the distribution channel, the global generic drug market is divided into hospital, retail, and online pharmacy.

Regional Perspectives
North America continues to dominate the global generic drugs market, supported by a strong presence of established pharmaceutical companies and favorable regulatory pathways for generic approvals. The United States, in particular, benefits from a well-working healthcare system and robust demand for cost-effective alternatives to branded drugs. Government policies such as the Hatch-Waxman Act and initiatives to encourage generic substitution have further accelerated market growth. Canada also plays a role, with its expanding portfolio of generics catering to both domestic needs and export demands.
Europe holds a significant share of the market, with countries like Germany, the UK, and France leading in generic drug adoption. Stringent price control mechanisms and reimbursement policies across the region drive the preference for generics over branded products. The European Medicines Agency’s streamlined approval process aids in faster market entry for new generic formulations. Eastern European nations are witnessing rising consumption, thanks to increasing healthcare access and cost-sensitive patient populations.
The Asia-Pacific region is emerging as a high-growth market for generic drugs, fueled by large populations and the growing burden of chronic diseases. India remains a global powerhouse for generic manufacturing, exporting extensively to the US, Europe, and other regions. China’s focus on healthcare reforms and the promotion of low-cost medicines is also propelling the sector. Other markets such as Japan and Australia are seeing increased uptake due to aging populations and government-led cost-containment efforts.
In the Rest of the World segment, Latin America, the Middle East, and Africa are experiencing steady growth in generic drug adoption. Brazil and Mexico are notable Latin American markets, benefiting from government procurement programs and local manufacturing capacity. The Middle East is investing in domestic production to reduce dependence on imports, while African countries are gradually improving their regulatory frameworks. Rising healthcare infrastructure and growing awareness of generics are expected to support long-term market expansion.

Major Competitors
Key competitors in the global generic drugs market are Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Sun Pharmaceuticals Industries, Fresenius Kabi, Lupin Pharmaceuticals, Inc., Endo International plc, Aurobindo Pharma, Aspen Holdings, Cipla Ltd., and Fresenius SE & Co. KGaA.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ...... 17
2 MARKET INTRODUCTION ... 19
2.1 DEFINITION ........ 19
2.2 SCOPE OF THE STUDY ........... 19
2.3 RESEARCH OBJECTIVE .......... 19
2.4 MARKET STRUCTURE ........... 19
3 RESEARCH METHODOLOGY .................. 20
3.1 OVERVIEW ......... 20
3.2 DATA FLOW ....... 22
3.2.1 DATA MINING PROCESS ... 22
3.3 PURCHASED DATABASE: ...... 23
3.4 SECONDARY SOURCES: ........ 24
3.4.1 SECONDARY RESEARCH DATA FLOW: .... 25
3.5 PRIMARY RESEARCH: ........... 26
3.5.1 PRIMARY RESEARCH DATA FLOW: ........ 27
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED .......... 28
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE .............. 28
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ...... 29
3.6.1 REVENUE ANALYSIS APPROACH ............ 29
3.7 DATA FORECASTING............. 30
3.7.1 DATA FORECASTING TYPE ..................... 30
3.8 DATA MODELING .................. 31
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ... 31
3.8.2 DATA MODELING: ............. 32
3.9 TEAMS AND ANALYST CONTRIBUTION ..................... 34
4 MARKET DYNAMICS ........... 36
4.1 INTRODUCTION ..................... 36
4.2 DRIVERS .............. 36
4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ACROSS THE GLOBE ................. 36
4.2.2 RISING STRATEGIC INITIATIVES BY MARKET PLAYERS ..................... 37
4.2.3 RISING DEMAND FOR AFFORDABLE MEDICATIONS ...... 38
4.3 RESTRAINTS ....... 39
4.3.1 VOLUNTARY PRODUCT RECALLS FROM MARKET PLAYERS ............... 39
4.3.2 BRAND LOYALTY AND DOCTOR PREFERENCES ............ 40
4.4 OPPORTUNITY .. 41
4.4.1 INVESMTENT ON RESEARCH & DEVELOPMENT (R&D) FOR GENERIC MEDICINE ....... 41
4.4.2 RISING AGING POPULATION .................. 41
5 MARKET FACTOR ANALYSIS .................. 42
5.1 PORTER'S FIVE FORCES MODEL .............. 42
5.1.1 THREAT OF NEW ENTRANTS .................. 42
5.1.2 BARGAINING POWER OF SUPPLIERS ...... 43
5.1.3 THREAT OF SUBSTITUTES ..................... 43
5.1.4 BARGAINING POWER OF BUYERS ........... 43
5.1.5 INTENSITY OF RIVALRY .... 43
5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET .............. 44
6 GLOBAL GENERIC DRUGS MARKET, BY INDICATION .................... 46
6.1 OVERVIEW ......... 46
6.2 CENTRAL NERVOUS SYSTEM (CNS) ........ 48
6.3 CARDIOVASCULAR ............... 49
6.4 UROLOGY ........... 49
6.5 ONCOLOGY ........ 49
6.6 RESPIRATORY .... 50
6.7 OTHERS ............... 50
7 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION ............ 51
7.1 OVERVIEW ......... 51
7.2 ORAL .................... 53
7.3 TOPICAL.............. 54
7.4 PARENTERAL ..... 54
7.5 OTHERS ............... 54
8 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL .................. 55
8.1 OVERVIEW ......... 55
8.2 HOSPITAL PHARMACY ......... 57
8.3 RETAIL PHARMACY .............. 57
8.4 ONLINE PHARMACY ............. 58
9 GLOBAL GENERIC DRUGS MARKET, BY REGION ..... 59
9.1 OVERVIEW ......... 59
9.2 NORTH AMERICA .................. 60
9.2.1 US............... 63
9.2.2 CANADA ..... 64
9.3 EUROPE ............... 65
9.3.1 GERMANY ... 68
9.3.2 FRANCE ...... 69
9.3.3 UK .............. 70
9.3.4 ITALY .......... 71
9.3.5 SPAIN ......... 72
9.3.6 REST OF EUROPE .............. 73
9.4 ASIA-PACIFIC ..... 75
9.4.1 CHINA ......... 78
9.4.2 INDIA .......... 79
9.4.3 JAPAN ........ 80
9.4.4 SOUTH KOREA .................. 81
9.4.5 AUSTRALIA . 82
9.4.6 REST OF ASIA-PACIFIC ..... 84
9.5 REST OF THE WORLD ........... 86
9.5.1 MIDDLE EAST ................... 88
9.5.2 AFRICA ....... 90
9.5.3 SOUTH AMERICA .............. 91
10 COMPETITIVE LANDSCAPE .................... 94
10.1 INTRODUCTION ..................... 94
10.2 MARKET SHARE ANALYSIS, 2024 ............. 94
10.3 COMPETITOR DASHBOARD ..................... 95
10.4 PUBLIC PLAYERS STOCK SUMMARY ...... 96
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL ................ 96
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ....... 97
10.6.1 PRODUCT LAUNCH ........... 97
10.6.2 PRODUCT LAUNCH / PRODUCT APPROVAL ................. 97
10.6.3 EXPANSION ..................... 99
11 COMPANY PROFILES ......... 100
11.1 SUN PHARMACEUTICAL INDUSTRIES LTD. ............... 100
11.1.1 COMPANY OVERVIEW ....... 100
11.1.2 FINANCIAL OVERVIEW ...... 101
11.1.3 PRODUCTS OFFERED ........ 102
11.1.4 KEY DEVELOPMENTS ........ 103
11.1.5 SWOT ANALYSIS .............. 103
11.1.6 KEY STRATEGIES .............. 104
11.2 LUPIN PHARMACEUTICALS, INC. ............ 105
11.2.1 COMPANY OVERVIEW ....... 105
11.2.2 FINANCIAL OVERVIEW ...... 106
11.2.3 PRODUCTS OFFERED ........ 107
11.2.4 KEY DEVELOPMENTS ........ 108
11.2.5 SWOT ANALYSIS .............. 109
11.2.6 KEY STRATEGIES .............. 109
11.3 ENDO INTERNATIONAL PLC .................... 110
11.3.1 COMPANY OVERVIEW ....... 110
11.3.2 FINANCIAL OVERVIEW ...... 111
11.3.3 PRODUCTS OFFERED ........ 111
11.3.4 KEY DEVELOPMENTS ........ 112
11.3.5 KEY STRATEGIES .............. 112
11.4 AUROBINDO PHARMA ......... 113
11.4.1 COMPANY OVERVIEW ....... 113
11.4.2 FINANCIAL OVERVIEW ...... 114
11.4.3 PRODUCTS OFFERED ........ 115
11.4.4 KEY DEVELOPMENTS ........ 116
11.4.5 KEY STRATEGIES .............. 116
11.5 ASPEN HOLDINGS .................. 117
11.5.1 COMPANY OVERVIEW ....... 117
11.5.2 FINANCIAL OVERVIEW ...... 118
11.5.3 PRODUCTS OFFERED ........ 119
11.5.4 KEY DEVELOPMENTS ........ 119
11.5.5 KEY STRATEGIES .............. 119
11.6 CIPLA LTD .......... 120
11.6.1 COMPANY OVERVIEW ....... 120
11.6.2 FINANCIAL OVERVIEW ...... 121
11.6.3 PRODUCTS OFFERED ........ 121
11.6.4 KEY DEVELOPMENTS ........ 123
11.6.5 SWOT ANALYSIS .............. 124
11.6.6 KEY STRATEGIES .............. 124
11.7 NOVARTIS AG .... 125
11.7.1 COMPANY OVERVIEW ....... 125
11.7.2 FINANCIAL OVERVIEW ...... 126
11.7.3 PRODUCTS OFFERED ........ 126
11.7.4 KEY DEVELOPMENTS ........ 127
11.7.5 SWOT ANALYSIS .............. 128
11.7.6 KEY STRATEGIES .............. 128
11.8 TEVA PHARMACEUTICAL INDUSTRIES LTD .............. 129
11.8.1 COMPANY OVERVIEW ....... 129
11.8.2 FINANCIAL OVERVIEW ...... 130
11.8.3 PRODUCTS OFFERED ........ 130
11.8.4 KEY DEVELOPMENTS ........ 131
11.8.5 SWOT ANALYSIS .............. 132
11.8.6 KEY STRATEGIES .............. 132
11.9 FRESENIUS SE & CO. KGAA .. 133
11.9.1 COMPANY OVERVIEW ....... 133
11.9.2 FINANCIAL OVERVIEW ...... 134
11.9.3 PRODUCTS OFFERED ........ 134
11.9.4 KEY DEVELOPMENTS ........ 137
11.9.5 KEY STRATEGIES .............. 137
11.10 VIATRIS INC. ...... 138
11.10.1 COMPANY OVERVIEW ....... 138
11.10.2 FINANCIAL OVERVIEW ...... 139
11.10.3 PRODUCTS OFFERED ........ 139
11.10.4 KEY DEVELOPMENTS ........ 140
11.10.5 KEY STRATEGIES .............. 141
12 DATA CITATIONS ................ 142